复发性乳腺癌

Sept. 24, 2026

研究

妙佑医疗国际的医生和科学家正在研究如何更好地预防、诊断和治疗复发性乳腺癌。

妙佑医疗国际综合癌症中心是获得美国国家癌症研究所乳腺癌研究卓越研究专科项目(SPORE)资助的少数几家机构之一。

妙佑医疗国际的医生和研究人员正在研究针对复发性乳腺癌的新兴技术和疗法,包括:

  • CAR-T 细胞疗法,通过对人体的免疫细胞进行重新编程,以帮助识别并攻击癌细胞。
  • 治疗性乳腺癌疫苗,旨在帮助免疫系统识别乳腺癌细胞并对其作出反应。
  • 放射诊疗一体化,该技术将先进的影像学检查与靶向放射治疗相结合,利用放射性药物将辐射更精准地递送至癌细胞。
  • 分子谱分析和生物标志物检测,以更好地了解癌症并协助指导个体化治疗决策。
  • 基于血液的检测,包括循环肿瘤 DNA(ctDNA)检测,旨在帮助监测癌症活动并指导随后的治疗计划制定。
  • 针对激素受体阳性、HER2 阳性、HER2 低表达和三阴性乳腺癌的新型靶向治疗。
  • 口服靶向药物,旨在治疗具有特定基因改变或对既往治疗产生耐药性的癌症。
  • 帮助免疫系统识别并攻击癌细胞的免疫疗法。
  • 将标准疗法与新型靶向疗法或免疫基础疗法相结合的联合治疗方案。
  • 先进的影像学方法,包括专门的 PET 成像,以协助识别复发癌症的活跃部位并指导治疗决策。
  • 针对复发性、转移性和难治性乳腺癌的临床试验,这些试验可能提供获得新兴疗法和新治疗方案的机会。

著述

请参阅美国国家医学图书馆检索服务系统 PubMed 所收录的妙佑医疗国际的医生在复发性乳腺癌领域的著述目录。

  1. Niederhuber JE, et al., eds. Cancer of the breast. In: Abeloff's Clinical Oncology. 6th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed March 4, 2026.
  2. Breast cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419. Accessed May 11, 2026.
  3. Klimberg VS, et al., eds. Bland and Copeland's The Breast: Comprehensive Management of Benign and Malignant Diseases. 6th ed. Elsevier; 2024. https://www.clinicalkey.com. Accessed March 4, 2026.
  4. Distress management. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1431. Accessed Feb. 2, 2026.
  5. Ruddy KJ, et al. Approach to the patient following treatment for breast cancer. https://www.uptodate.com/contents/search. Accessed March 4, 2026.
  6. Runowicz CD, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. CA: A Cancer Journal for Clinicians. 2016; doi:10.3322/caac.21319.
  7. Eisen A, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update. Journal of Clinical Oncology. 2022; doi:10.1200/JCO.21.02647.
  8. Chirgwin JH, et al. Treatment adherence and its impact on disease-free survival in the Breast International Group I-98 trial of tamoxifen and letrozole, alone and in sequence. Journal of Clinical Oncology. 2016; doi:10.1200/JCO.2015.63.8619.
  9. DeVita VT Jr, et al., eds. Breast cancer. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. ProQuest Ebook Central. Wolters Kluwer; 2023. Accessed Feb 2, 2026.
  10. Medical review (expert opinion). Mayo Clinic. March 18, 2025.
  11. Antibody-drug conjugate. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/antibody-drug-conjugate. Accessed March 23, 2026.
  12. Come SE. Overview of long-term complications of therapy in breast cancer survivors and patterns of relapse. https://www.uptodate.com/contents/search. Accessed May 11, 2026.
  13. Pedersen RN, et al. The incidence of breast cancer recurrence 10-32 years after primary diagnosis. Journal of the National Cancer Institute. 2022; doi:10.1093/jnci/djab202.
  14. Sabel MS, et al. Clinical manifestations and evaluation of locoregional recurrences of breast cancer. https://www.uptodate.com/contents/search. Accessed May 21, 2026.
  15. Bleiweiss IJ. Pathology of breast cancer. https://www.uptodate.com/contents/search. Accessed May 8, 2026.
  16. Andre F, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. Journal of Clinical Oncology. 2022; doi:10.1200/JCO.22.00069.
  17. Yau C, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: A multicentre pooled analysis of 5,161 patients. The Lancet Oncology. 2022; doi:10.1016/S1470-2045(21)00589-1.
  18. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: A meta-analysis of 13 864 women in seven randomised trials. The Lancet Oncology. 2021; doi:10.1016/S1470-2045(21)00288-6.
  19. Ko A, et al. Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: A systematic review and meta-analysis. Annals of Internal Medicine. 2026; doi:10.7326/ANNALS-25-02237.
  20. Rock CL, et al. American Cancer Society nutrition and physical activity guide for cancer survivors. CA: A Cancer Journal for Clinicians. 2022; doi:10.3322/caac.21719.
  21. Panet F, et al. Use of ctDNA in early breast cancer: Analytical validity and clinical potential. NPJ Breast Cancer. 2024; doi:10.1038/s41523-024-00653-3.
  22. Breast SPOREs. National Cancer Institute. https://dctd.cancer.gov/research/spores/focus-area/breast. Accessed April 17, 2026.
  23. Member institutions. Alliance for Clinical Trials in Oncology. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FInstitutions. Accessed April 17, 2026.